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ABSTRACT
Objective: Emergence of extended-spectrum beta-lactamases (ESBLs) production poses another clinical problem with Gram-negative bacterial 
infections. The present study was aimed to evaluate the ESBL producers among various clinical samples of clinically suspected patients.
Methods: A total of 1279 samples (urine [918], pus [207] and stool [154]) were collected and 465 isolates (Escherichia coli [320], Enterobacter 
aerogenes [119] and Klebsiella pneumoniae [26]) were isolated and screened for the presence of ESBL producers using combination disc method and 
double disc synergy test.
Results: Of the 465 culture positive isolates, 130 (E. coli 93 [29.06%], E. aerogenes 35 [29.41%] and K. pneumoniae 2 [7.69%]) were identified as ESBL 
producers. Among the three Enterobacteriaceae members, E. coli 93 (29.06%) was found to be predominant ESBL producer next in order E. aerogenes 
35 (29.41%) and K. pneumoniae 2 (7.69%). Maximum number of ESBL producers were recovered from urine (n=111) followed by pus (n=14) and stool 
(n=5). All the ESBL-producing isolates were subjected to antibiotic sensitivity test using 10 different antibiotics. ESBL producers were chiefly resistance 
to ceftriaxone followed by ceftazidime and cefotaxime. Of 130 ESBL producers, 15 (E. coli (8), E. aerogenes (6) and K. pneumoniae (1)] strains were 
selected for genotypic identification. Among, only two strains of E. aerogenes were positive isolates for CTX-M type ESBL in polymerase chain reaction.
Conclusion: This study concluded that among Enterobacteriaceae members, E. coli was the predominant ESBL producers and urine was noted as the 
prime source for the ESBL positive isolates when compared to other source. Genotypic identification was the best method to differentiate ESBL types 
which were essential to provide proper treatment.
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INTRODUCTION
Infections caused by extended-spectrum beta-lactamase (ESBL)-
producing, Gram-negative bacteria are associated with increased 
morbidity and mortality, which is linked to inappropriate or delayed 
antimicrobial treatment [1]. Since the introduction to the extended 
spectrum cephalosporins into clinical use, strains expressing ESBL have 
been reported from to the world in increasing numbers [2]. There is no 
consensus on the precise definition of ESBLs. A commonly used working 
definition is that the ESBLs are β-lactamases capable of hydrolysis of 
the antibiotics such as penicillins, first-, second- and third-generation 
cephalosporins and aztreonam (AT) (but not the cefamycins or 
carbapenems) and which are inhibited by β-lactamase inhibitors such 
as clavulanic acid [3]. The first report on plasmid-encoded β-lactamases 
capable of hydrolyzing the extended-spectrum cephalosporins was 
published in 1983 [4]. Among the family Enterobacteriaceae, the 
production of plasmid-mediated extended-spectrum β-lactamase 
(ESBLs) has emerged as an important mechanism of resistance to 
β-lactam drugs [5]. ESBLs have been found mainly in Klebsiella spp., 
and Escherichia coli, but have been also reported on other genera 
worldwide, such as Citrobacter, Enterobacter, Morganella, Proteus, 
Providencia, Salmonella, Serrati and P. seudomonas [6,7].
The ESBL genes are mostly plasmid-encoded [8], and most ESBLs 
can be divided into three genotypes: Temoniera (TEM), sulfhydryl 
variable (SHV), and CTX-M [3]. The predominant ESBL genotypes were 
TEM and SHV [9]. Most ESBLs are TEM and SHV enzyme derivatives 
characterized using a few point mutations at selected loci within the 
gene [2,10]. This enzyme was found in a blood culture isolate of E. coli 
from a Greek patient named TEM, hence the designation TEM [11]. 
The SHV-type ESBLs may be more frequently found in clinical isolates 
than any other type of ESBLs [12]. SHV refers to SHV. In addition, a 
genotype the CTX-M enzyme emerged worldwide when compared to 
TEM and SHV [9]. The plasmid-mediated ESBLs, which preferentially 
hydrolyze cefotaxime (CE) and are better inhibited by tazobactam than 
by sulbactam and clavulanate so-called as CTX-M enzymes [11]. In the 
1990s, a novel type of ESBL, the CTX-M enzyme, emerged worldwide [9]. 
The CTX-M types, now exceeding 50 different types, can be divided into 
five groups based on their amino acid identities: CTX-M-1, CTX-M-2, 
CTX-M-8, CTX-M-9, and CTX-M-25 [13]. These enzymes are not very 
closely related to TEM and SHV β -lactamases as they show only 40% 
identity with these enzymes [14].
Infections caused by ESBL-producing bacteria often involve immune-
compromised patients, making it difficult to eradicate these organisms 
in high-risk wards, such as intensive care units [15,16]. Drug 
susceptibility data are of major importance to the clinical management 
of patients infected by these organisms [10]. Thus, monitoring of the 
prevalence and the types of extended-spectrum β-Lactamase enzymes 
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may contribute to defining the degree of the problem with a specific 
geographical area, and to establish a proper treatment protocol [17]. The 
aim of this study was to determine the prevalence of ESBL-producing 
Enterobacteriaceae members of the Department of Microbiology, DDC 
laboratory in Tiruchirappalli, India.
MATERIALS AND METHODS
The study was conducted in the Doctor’s Diagnostic Centre, 
Tiruchirappalli, over a period of month from July to August 2013. 
A total of 1,279 consecutive, non-repetitive, Gram-negative isolates 
from various clinical samples such as urine (n=918), pus (n=207), and 
stool (n=154) were included in the study.
Isolation and identification
The cultures were isolated from selective agar, MacConkey agar, and 
blood agar (Himedia, Mumbai) to study their cultural characteristics. 
A single isolated colony was considered for further studies and 
identification was done using the standard procedure. Gram’s staining, 
morphological, cultural, and biochemical test were performed [18].
Antibiotic sensitivity test
The resistance to one or more 3rd generation cephalosporin’s 
(ceftazidime [CAZ], ceftriaxone (CTR), cefotaxime, etc.,) prompted 
us to detect ESBL producers, the common mechanism of beta-lactam 
resistance.
All the isolates were subjected to antimicrobial susceptibility agents 
and were determined using Disc Diffusion method of Kirby-Bauer [19] 
on Mueller-Hinton Agar as described by the Clinical and Laboratory 
Standard Institute (CLSI).The antibiotic discs used (HiMedia, Mumbai) 
were Cefoxitin (30 mcg), Cefepime (30 mcg), Cefepime+Tazobactam 
(30/10 mcg), CAZ (30 mcg), ceftazidime+tazobactam (30/10 mcg), CTR 
(30 mcg), Cephotaxime or CE (30 mcg), cephotaxime+clavulanic acid 
(30/10 mcg), imipenem (10 mcg), and AT (30 mcg) [20].
Combination disc method
The combination disc test using both CE and CAZ, alone and in 
combination with clavulanic acid, was performed for the detection 
of ESBL according to the CLSI guidelines. In this test, an overnight 
culture suspension of the test isolate which was adjusted to 0.5 
McFarland standards was inoculated using sterile cotton swab 
on the surface of a Mueller-Hinton agar plate. The CE (30 μg) and 
cefotaxime-clavulanic acid (30/10 μg) disks were placed 20 mm 
apart on the agar. Similarly, CAZ (30 μg) and ceftazidime-clavulanic 
acid (30 μg/10 μg) disks were placed 20 mm apart. After incubating 
overnight at 37°C, ≥5 mm increase from the zone diameter for either 
antimicrobial agent which was tested in combination with clavulanic 
acid. Its zone, when tested for, was interpreted as positive for ESBL 
production [21].
Double disc synergy test
The test inoculums (0.5 McFarland tube) was spread as a lawn onto 
Mueller-Hinton agar (MHA) plate using a sterile cotton swab. A disc 
of CAZ (30 μg)+clavulanic acid (10 μg) was placed on the surface of 
MHA, then the disc of CAZ (30 μg) was placed at the distance of 15 mm 
from the ceftazidime+clavulanic acid disc by the edge to edge. The 
inoculated plates were incubated at 35°C in the incubator for 18–24 h. 
The zone of inhibition between the CAZ and ceftazidime+clavulanic 
acid was compared. The difference in the zone diameter of ≥5 mm was 
interpreted as positive for ESBL production [22].
Molecular identification
Isolation of DNA
TE buffer was added to overnight grown cells by gentle pipetting. Then, 
each of the tubes were added with 30 µl of 10% SDS and 3 µl of 20 mg/ml 
Proteinase K. The tubes were vortexed and then incubated at 37°C for 1 
h. A volume of 100 µl of CTAB/NaCl solution was added to 150 µl of 5 M 
NaCl, mixed well and incubated at 65°C for 10 min and an equal volume 
of chloroform:Isoamyl alcohol mixture was added and centrifuged. 
The aqueous viscous supernatant was transferred to fresh tubes equal 
volumes of phenol:chloroform:isoamyl alcohol (25:24:4) was added. 
After centrifugation, to the supernatant ice-cold isopropanol was added 
and mixed well. The pellets were washed with 70% ethanol, and the 
nucleic acids were recovered by centrifugation. The pellets were then 
kept for drying after the complete removal of the supernatant and 
finally resuspended in 15 µl of distilled water and stored at 4°C [23]. 
Polymerase chain reaction (PCR) amplification for CTX-M was carried 
out for all the isolates, based on the producers described by Woodford 
et al. [24]. After this, the amplified DNA fragments were purified from 
agarose gels using QIA gel extraction kit manufacturer’s protocol and 
sequenced using forward and reverse about 771 bp were carried out in 
Xcelris, Ahmedabad.
RESULTS
A total of 1279 various clinical samples were recovered from 
clinically suspected patients which include, urine 918 (71.77%), 
pus 207 (16.18%), and stool 154 (12.04%). Based on the standard 
laboratory procedures, three Enterobacteriaceae members (E. coli 
320 [68.81%], Enterobacter. aerogenes 119 [25.59%] and Klebsiella 
pneumoniae 26 [5.59%]) are identified in Table 1.
Further, these 465 isolates were screened for the presence of ESBL 
producers using combination disc method and double disc synergy 
test. Of the 465 culture positive isolates, 130 (E. coli 93 [29.06%], 
E. aerogenes 35 [29.41%], and K. pneumoniae 2 [7.69%]) were identified 
as ESBL producers, and remaining 335 were nonESBL producers (E. coli 
93 [70.93%], E. aerogenes 35 (70.58%), and K. pneumoniae 2 (92.30%)] 
(Table 2).
A maximum number of ESBL producers were recovered from urine 
(n=111) followed by pus (n=14) and stool (n=5). Female patients 
were more prone to infection caused by ESBL producing isolates 78 
(urine [38], pus [10], and stool [4]) than male patients 52 (urine [73], 
pus [4], and stool [1]) (Fig. 1).
The susceptibility profile of ESBL producers is depicted in Fig. 2. Of 
the 10 antibacterial agents, a maximum number of ESBL producers 
were resistance to CTR (126/130) followed by CAZ (115/130) and 
CE (110/130). Interestingly, except one isolate (1/130), all the ESBL 
producers were susceptible to imipenem.
For the genotypic identification, 15 ESBL positive strains (E. coli [8], 
E. aerogenes [6] and K. pneumoniae [1]) were selected, among two 
strains of E. aerogenes were positive isolates for CTX-M type ESBL in 
PCR. The amplified CTX-M gene after gel elution was sequenced using 
forward and reverse, about 415 and 771 bp were carried out in, Xcelris, 
Ahmedabad. The sequences obtained were aligned with previously 
published sequences available in NCBI using BLAST [25]. The gene 
accession number was KJ131192.1 and KJ131193.1. The sequence of 
the amplified product was as follows.
KJ131192.1
GTTCACGCTG ATGGCGACGG CAACCGTCAC GCTGTTGTTA GGAAGTGTGC 
CGCTGTATGC
GCAAACGGCG GACGTACAGC AAAAACTTGC CGAATTAGAG CGGCAGTCGG 
GAGGCAGACT
GGGTGTGGCA TTGATTAACA CAGCAGATAA TTCGCAAATA CTTTATCGTG 
CTGATGAGCG
CTTTGCGATG TGCAGCACCA GTAAAGTGAT GGCCGCGGCC GCGGTGCTGA 
AGAAAAGTGA
AAGCGAACCG AATCTGTTAA ATCAGCGAGT TGAGATCAAA AAATCTGACC 
TTGTTAACTA
TAATCCGATT GCGGAAAAGC ACGTCAATGG GACGATGTCA CTGGCTGAGC 
TTAGCGCGGC
CGCGCTACAG TACAGCGATA ACGTG GCG
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KJ131193.1
CAGTTCACGC TGATGGCGAC GGCAACCGTC ACGCTGTTGT TAGGAAGTGT 
GCCGCTGTAT
GCGCAAACGG CGGACGTACA GCAAAAACTT GCCGAATTAG AGCGGCAGTC 
GGGAGGCAGA
CTGGGTGTGG CATTGATTAA CACAGCAGAT AATTCGCAAA TACTTTATCG 
TGCTGATGAG
CGCTTTGCGA TGTGCAGCAC CAGTAAAGTG ATGGCCGCGG CCGCGGTGCT 
GAAGAAAAGT
GAAAGCGAAC CGAATCTGTT AAATCAGCGA GTTGAGATCA 
AAAAATCTGA CCTTGTTAAC




In hospital environment, resistance of bacterial pathogens to common 
antibiotic therapies was increasing at an alarming  rate [26]. The 
use of antibiotics for any infection causes a “selective pressure” on 
bacterial populations, which emerge the resistant mutants and it can 
flourish [27]. The incidence of ESBL producing strains of clinical isolates 
has been steadily increasing from the past years resulting in limitation 
of therapeutic options [28]. These bacteria are showing rising rates of 
resistance to current therapies [29]. The problems which are associated 
with ESBLs include multidrug resistance, difficulty in detection and 
treatment, and increased mortality. ESBL-producing organisms, being 
the most common nosocomial pathogens, it is essential to detect and 
treat them as early as possible [30].
Nosocomial infections with Gram-negative bacilli are not uncommon 
for the local setting and can be perceived as a growing threat to public 
health [31]. In this study, out of 1279 different clinical samples, 465-Gram-
negative isolates were recovered among that E. coli 320 (68.81%), 
E. aerogenes 119 (25.59%), and K. pneumoniae 26 (5.59%). Similarly, a 
previous study recorded that, E. coli (42.4%) was the most predominant 
isolate followed by K. pneumoniae (28.5%) [32]. However, the study 
conducted by Nazneen et al. (47%) [31], Menon et al. (47.14%) [33], 
Shobha et al. (45.62%) [34], and Nevine et al. (41.17%) [35] recorded 
that K. pneumoniae was the predominant isolate.
The important reason for its detection is a failure to treat ESBL-producing 
organisms due to limited therapeutic choices [36]. The isolates resistant 
to cefotaxime were tested for ESBL production by double disc synergy 
test method [37-39]. Similarly, in the present study, ESBL production was 
detected using combination disc method and double disk synergy test. 
Similarly, a study conducted by Umadevi et al. [30] used the combination 
disc method, and some other studies used the double disk synergy test 
of the detection of ESBL producer [40-43].
ESBL-producing organisms predominantly isolated from urine 
sample [31,44-47]. Similarly, in our study, urine sample (85.38%) was 
the major source of ESBL producing strains followed by pus (10.76%) 
and stool (3.84%). However, a study by Sharma et al. [41] recorded that 
high prevalence of ESBL producers we isolated from respiratory tract 
samples (63.83%) was the major source of ESBL-producing strains 
followed by stool samples, urine, body fluid, pus, and blood.
The sex plays an important role in the infection which was affected by 
Gram-negative ESBL-producing organisms. A study by Shah et al. [48] 
was documented that male patients 10 (62.50%) were predominant 
than female 6 (37.50%) for the ESBL producers. Conversely, in our 
study, ESBL-producing isolates were predominantly recorded in female 
(n=78) than male (n=52). ESBL-producing isolates from urine were 
more common to males than females, in agreement with a previous 
report [49]. Contrary, in our study, male patients were more prevalent 
to ESBL in pus (10) and stool (5) samples than the female patients. On 
the other hand, ESBL prevalence in female patients was found to be the 
highest in urine samples (73).
Table 1: Frequency of Gram-negative bacteria among various 
clinical samples
Sample Culture positive
E. coli E. aerogenes K. pneumoniae Total
Urine (n=918) 253 101 18 372
Pus (n=207) 34 18 8 60
Stool (n=154) 33 - - 33
Total 320 119 26 465
Escherichia coli: E. coli, Enterobacter aerogenes: E. aerogenes, Klebsiella 
pneumonia: K. pneumonia, ESBL: Extended-spectrum beta-lactamase
Table 2: Detection of ESBL production in E. coli, E. aerogenes and K. pneumoniae
Sample ESBL producers NonESBL producers 
E. coli E. aerogenes K. pneumoniae Total E. coli E. aerogenes K. pneumoniae Total
Urine 80 30 1 111 173 71 17 261
Pus 8 5 1 14 26 13 7 46
Stool 5 - - 5 28 - - 28
Total 93 35 2 130 227 84 24 335
Escherichia coli: E. coli, Enterobacter aerogenes: E. aerogenes, Klebsiella pneumonia: K. pneumonia, ESBL: Extended-spectrum beta-lactamase
Fig. 1: Prevalence of extended-spectrum beta-lactamase over the 
sex distribution
Fig. 2: Resistant patterns of extended-spectrum beta-lactamase 
producers from different sample
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According to the geographical region, the fraction of putative ESBL-
producing isolates can vary. These variations could be due to the 
differences in selecting a type of antibiotic, antibiotic selection pressure, 
local antibiotic, and prescribing habits, which differ from state to state, 
country to country, and from institution to institution. The prevalence 
of ESBL-producing bacteria has been on the rise, particularly in Asia 
compared to other regions [50]. A study from China, the figures of ESBL 
producers vary between 25 and 40% [51]. In India, the prevalence rate 
varies in different institutions from 28% to 84% [52], but Ali et al. [53] 
reported that ESBL producers making a frequency of 45 %. Another 
study recorded that ESBL production was found to be 52.49% [41]. 
Similarly, a study from Malaysia in 2001 by Nurul et al. [54] depicted a 
prevalence of ESBL as 58.6 %. A recent study in 2005, from New Delhi, 
showed 68.78 % of the strains of Gram-negative bacteria to be ESBL 
producers [55]. A study by Nazneen et al. [31], Mathur et al. [56], 
and Nevine et al. [35] noted 61%, 68%, and 65.8% of ESBL producer 
correspondingly, these prevalence were quite high when compared to 
our studies. Differently, in our study, the prevalence of ESBL producers 
was 27.95%. A study by Basavaraj et al. [57] from Karnataka and 
Sharma and Grover [58] from Himachal-Pradesh reported an incidence 
of 32.1% and 38.5% which is slightly accordance with our results. 
While studies conducted by Rodrigues et al. [59], Kumar et al. [60], and 
Menon et al. [33] reported 6.9%, 19.8%, and 20% respectively, which 
were quite low when compared to our study.
ESBLs in Gram-negative bacteria have emerged as a major problem 
of hospitalized as well as community-based patients [31]. Important 
ESBL-producing Gram-negative bacilli includes K. pneumoniae, E. coli, 
and P. mirabilis, Enterobacterspp., Citrobacter freundii, P. aeruginosa, 
Acinetobacter and Stenotrophomonas maltophilia [61]. A study from 
Egypt reported that 46% of ESBL-producing isolates of K. pneumoniae 
were from the clinical isolates [62]. ESBL are more prevalent in Klebsiella 
spp. followed by E. coli [63]. Similarly, a study by Nazneen et al. [31], 
Mathur et al. [56], Gupta et al. [64], Sharma et al. [41], and Ali et al. [53], 
were reported that, K. pneumoniae 74%, 73%, 71%, 67%, and 57% was 
more prevalent than E. coli 62%, 62%, 64%, 57%, and 39.1%, respectively. 
Conversely, in the present study, the highest incidence of ESBL was noted 
in E. coli (29.06%), E. aerogenes (29.41%), and K. pneumoniae (7.69%).
Klebsiella is the genus which frequently harbors ESBL [65]. However, 
in other studies, E. coli was the major ESBL producer [30,44,66,67]. 
Similarly, in the present study, the highest incidence of ESBL was 
noted in E. coli (29.06%), E. aerogenes (29.41%) and K. pneumoniae 
(7.69%). Following studies were also reported that E. coli was the 
predominant ESBL producers. A study reported that 81% of the E. coli 
and 74 % of the K. pneumoniae isolates were ESBL producers [30]. In 
the same way, a study noted that the highest ESBL producer was E. coli 
(64.2%) followed by K. pneumoniae (60.1%) [32]. Another study from 
southern India reported an incidence of 58.06% for ESBL producing 
E. coli and 57.14% for ESBL-producing Enterobacter spp. [68]. A similar 
prevalence was observed that 55.69% (n=93) were E. coli and 44.31% 
(n=74) were K. pneumoniae isolates were ESBL producer [69]. Shrestha 
et al. [70] reported that the prevalence of ESBL-producing organisms 
was found to be 54 (18%); among which E. coli was 29 (53.7%), 
K. pneumoniae (14.8%). A study by Jain et al. reported that maximum 
ESBL producers were found among E. coli isolates (80.9%) followed by 
K. pneumoniae (75%) [71]. A report from Coimbatore (India) showed 
that ESBL production was 41% in E. coli and 40% in K. pneumoniae [72]. 
Kulkarni et al. [47] in their study reported that E. coli (40.7%) was the 
most frequent and K. pneumoniae (15.9%).
CONCLUSION
The study results suggested that, among Enterobacteriaceae members, 
E. coli was the predominant ESBL producers and urine was noted as the 
prime source for the ESBL positive isolates when compared to another 
source. Although many phenotypic methods were available, genotypic 
identification was the best method to differentiate ESBL types which 
were essential to provide proper treatment. Constant and careful 
surveillance, proper detection methods, and proper management are 
recommended to control the spread of these organisms as the infections 
by ESBL-producing organisms.
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